Oramed Failure Highlights Insurmountable Challenge Of Oral Insulin Delivery
Israeli Firm's Candidate Suffers Phase III Flop
Oramed's attempts to advance an oral formulation of insulin for type 2 diabetes patients have been scuppered with a Phase III fail that has sunk the stock.
You may also be interested in...
Public Company Edition: Mineralys launches the second $100m-plus initial public offering of 2023 and trades higher in its first day. Also, Collegium sells $210m worth of notes, Eliem cuts 55% of its jobs at it shifts to preclinical and Aligos de-prioritizes hepatitis B while reducing its workforce another 10%.
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.